Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations

Romain Deschamps; Caroline Papeix; Xavier Ayrignac; Bertrand Bourre; Jonathan Ciron; Mikael Cohen; Nicolas Collongues; Kumaran Deiva; Françoise Durand Dubief; David-Axel Laplaud; Elisabeth Maillart; Laure Michel; Julie Pique; Aurélie Ruet; Eric Thouvenot; Hélène Zéphir; Romain Marignier; Bertrand Audoin

doi:10.1016/j.neurol.2024.06.003

Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations

Rev Neurol (Paris). 2024 Oct;180(8):711-714. doi: 10.1016/j.neurol.2024.06.003. Epub 2024 Jul 4.

Authors

Romain Deschamps¹, Caroline Papeix², Xavier Ayrignac³, Bertrand Bourre⁴, Jonathan Ciron⁵, Mikael Cohen⁶, Nicolas Collongues⁷, Kumaran Deiva⁸, Françoise Durand Dubief⁹, David-Axel Laplaud¹⁰, Elisabeth Maillart¹¹, Laure Michel¹², Julie Pique⁹, Aurélie Ruet¹³, Eric Thouvenot¹⁴, Hélène Zéphir¹⁵, Romain Marignier⁹, Bertrand Audoin¹⁶

Affiliations

¹ Department of Neurology, hôpital Fondation Adolphe-de-Rothschild, Paris, France. Electronic address: rdeschamps@for.paris.
² Department of Neurology, hôpital Fondation Adolphe-de-Rothschild, Paris, France.
³ Department of Neurology, University Hospital of Montpellier, Montpellier, France.
⁴ Department of Neurology, University Hospital of Rouen, Rouen, France.
⁵ Department of Neurology, University Hospital of Toulouse, Toulouse, France.
⁶ CRC-SEP neurologie Pasteur 2, CHU de Nice, université Cote d'Azur, UMR2CA (URRIS), Nice, France.
⁷ Department of Neurology and Department of Pharmacology, Addictology, Toxicology and Therapeutics, Center for Clinical Investigation, Inserm U1434, Biopathology of Myelin, Neuroprotection and Therapeutic Strategy, Inserm U1119, Strasbourg University, Strasbourg, France.
⁸ Department of Pediatric Neurology, Bicêtre Hospital, Assistance publique-Hôpitaux de Paris, University Hospitals Paris-Saclay, Le Kremlin-Bicêtre, France.
⁹ Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM), hôpital neurologique Pierre-Wertheimer, Lyon University Hospital, Lyon, France.
¹⁰ Department of Neurology, CR2TI-Inserm U1064, CIC1314, CHU de Nantes, Nantes université, Nantes, France.
¹¹ Department of Neurology, centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM), hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
¹² Department of Neurology, Inserm UMR 1236, CHU de Rennes, université de Rennes 1, Rennes, France.
¹³ Department of Neurology, University Hospital of Bordeaux, Bordeaux, France.
¹⁴ Department of Neurology, University Hospital of Nîmes, Nîmes, France.
¹⁵ Department of Neurology, U 1172, CRC-SEP, University Hospital of Lille, Lille, France.
¹⁶ Department of Neurology, pôle de neurosciences cliniques, hôpital de la Timone, Marseille, AP-HM, Aix Marseille University, Marseille, France.

PMID: 38969609
DOI: 10.1016/j.neurol.2024.06.003

No abstract available

Publication types

Letter
Editorial

MeSH terms

Aquaporin 4* / immunology
Cost-Benefit Analysis*
France / epidemiology
Humans
Immunologic Factors / economics
Immunologic Factors / therapeutic use
Neuromyelitis Optica* / drug therapy
Neuromyelitis Optica* / economics
Rituximab* / economics
Rituximab* / therapeutic use
Treatment Outcome

Substances

Rituximab
Aquaporin 4
AQP4 protein, human
Immunologic Factors